Drug profile

The FDA adverse-event record for Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment

43 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment. See the species affected, top reactions, and outcomes below.

43
adverse-event reports
14.0%
death-coded share
Dog
most-reported species
12
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
43
Total Reports
6
Deaths Reported
14.0%
Death Rate

Active Ingredients

Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment

Administration Routes

UnknownAuricular (Otic)Topical

Species Affected

Dog 35
Cat 8

Most Affected Breeds

Domestic Shorthair 6
Retriever - Labrador 6
Shiba Inu 4
Spaniel - Cocker American 2
Bulldog - French 2
Dog (other) 2
Dog (unknown) 2
Terrier - Irish Soft-coated Wheaten 1
Retriever - Golden 1
Lhasa Apso 1

Most Reported Reactions

Vomiting 12
Lethargy (see also Central nervous system depression in 'Neurological') 10
Lack of efficacy - NOS 4
Other abnormal test result NOS 4
Seizure NOS 4
Ear discharge 4
Decreased appetite 4
Dehydration 3
Death by euthanasia 3
Behavioural disorder NOS 3
Other ear disorder NOS 3
Depression 3

Outcome Breakdown

Ongoing
17 (39.5%)
Outcome Unknown
12 (27.9%)
Recovered/Normal
8 (18.6%)
Died
3 (7.0%)
Euthanized
3 (7.0%)

Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment Adverse Event Insights

43 reports name Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment; 6 recorded a death outcome (14.0% of reported events, not a population-level mortality rate). Active ingredient: Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment. Administration routes: Unknown, Auricular (Otic), Topical.

By species: Dog (35 reports), Cat (8 reports). By breed: Domestic Shorthair (6), Retriever - Labrador (6), Shiba Inu (4).

Leading clinical signs: Vomiting (12), Lethargy (see also Central nervous system depression in 'Neurological') (10), Lack of efficacy - NOS (4), Other abnormal test result NOS (4). Outcome, 43 coded reports: Ongoing leads at 39.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.